Gain Therapeutics (GANX) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gain Therapeutics (GANX) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 22.0% versus a loss of 36.5%. MAIA Biotechnology is the larger company by market cap ($75.9 million vs $71.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | MAIA |
|---|---|---|
| Share price | $1.63 | $1.23 |
| Market cap | $71.14M | $75.94M |
| 1-day change | +0.93% | +6.96% |
| YTD return | -49.84% | -24.84% |
| 1-year return | -21.98% | -36.46% |
| 5-year return | -76.73% | — |
| Forward P/E | — | 1.11 |
| EPS (TTM) | $-0.50 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $3.19 |
| 52-week low | $1.53 | $0.87 |
| Distance from 52-week high | -62.44% | -61.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +341.72% | +875.61% |
| Average volume | 493.98K | 527.89K |
| Shares outstanding | 43.64M | 61.74M |
| Employees | 20 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed MAIA by 14.5 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
GANX vs MAIA FAQ
Which is bigger, Gain Therapeutics or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $75.94M compared with $71.14M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or MAIA?
GANX returned -21.98% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.